Logo image of BLU

BELLUS HEALTH INC (BLU) Stock Fundamental Analysis

NASDAQ:BLU - Nasdaq - CA07987C2040 - Common Stock - Currency: USD

14.74  0 (0%)

After market: 14.74 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BLU. BLU was compared to 549 industry peers in the Biotechnology industry. While BLU seems to be doing ok healthwise, there are quite some concerns on its profitability. BLU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BLU has reported negative net income.
In the past year BLU has reported a negative cash flow from operations.
In the past 5 years BLU always reported negative net income.
BLU had a negative operating cash flow in each of the past 5 years.
BLU Yearly Net Income VS EBIT VS OCF VS FCFBLU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

The profitability ratios for BLU are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLU Yearly ROA, ROE, ROICBLU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -10 -20

1.3 Margins

BLU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BLU Yearly Profit, Operating, Gross MarginsBLU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100K -200K -300K -400K

More info and screens

5

2. Health

2.1 Basic Checks

BLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLU has been increased compared to 1 year ago.
Compared to 1 year ago, BLU has a worse debt to assets ratio.
BLU Yearly Shares OutstandingBLU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
BLU Yearly Total Debt VS Total AssetsBLU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 103.35 indicates that BLU is not in any danger for bankruptcy at the moment.
The Altman-Z score of BLU (103.35) is better than 99.52% of its industry peers.
BLU has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BLU (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 103.35
ROIC/WACCN/A
WACC7.86%
BLU Yearly LT Debt VS Equity VS FCFBLU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 33.42 indicates that BLU has no problem at all paying its short term obligations.
BLU has a better Current ratio (33.42) than 97.91% of its industry peers.
A Quick Ratio of 33.42 indicates that BLU has no problem at all paying its short term obligations.
BLU has a Quick ratio of 33.42. This is amongst the best in the industry. BLU outperforms 97.91% of its industry peers.
Industry RankSector Rank
Current Ratio 33.42
Quick Ratio 33.42
BLU Yearly Current Assets VS Current LiabilitesBLU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

BLU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.00%, which is quite good.
Looking at the last year, BLU shows a decrease in Revenue. The Revenue has decreased by -6.25% in the last year.
Measured over the past years, BLU shows a very negative growth in Revenue. The Revenue has been decreasing by -34.23% on average per year.
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Sales Q2Q%-25%

3.2 Future

The Earnings Per Share is expected to grow by 35.40% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 654.86% on average over the next years. This is a very strong growth
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLU Yearly Revenue VS EstimatesBLU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BLU Yearly EPS VS EstimatesBLU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLU Price Earnings VS Forward Price EarningsBLU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLU Per share dataBLU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

BLU's earnings are expected to decrease with -9.80% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%

More info and screens

0

5. Dividend

5.1 Amount

BLU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BELLUS HEALTH INC

NASDAQ:BLU (6/28/2023, 8:00:02 PM)

After market: 14.74 0 (0%)

14.74

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2023-05-12/amc
Earnings (Next)08-08 2023-08-08/amc
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.87B
Analysts76
Price Target15.39 (4.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.73%
Min EPS beat(2)-13.15%
Max EPS beat(2)18.62%
EPS beat(4)1
Avg EPS beat(4)-4.1%
Min EPS beat(4)-20.01%
Max EPS beat(4)18.62%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)7.91%
Min Revenue beat(2)7.91%
Max Revenue beat(2)7.91%
Revenue beat(4)3
Avg Revenue beat(4)30.35%
Min Revenue beat(4)7.91%
Max Revenue beat(4)69.97%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.73%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 124601.15
P/FCF N/A
P/OCF N/A
P/B 5.07
P/tB 5.86
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.7
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS2.91
TBVpS2.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.42
Quick Ratio 33.42
Altman-Z 103.35
F-Score1
WACC7.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
EPS Next Y-27.52%
EPS Next 2Y-17.88%
EPS Next 3Y-9.8%
EPS Next 5Y35.4%
Revenue 1Y (TTM)-6.25%
Revenue growth 3Y-18.9%
Revenue growth 5Y-34.23%
Sales Q2Q%-25%
Revenue Next Year-35.9%
Revenue Next 2Y-19.94%
Revenue Next 3Y413.52%
Revenue Next 5Y654.86%
EBIT growth 1Y-24.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-150.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.96%
OCF growth 3YN/A
OCF growth 5YN/A